Literature DB >> 28275264

Experimental arthritis: Do you want to treat arthritis? IDO2!

Joanna Collison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28275264     DOI： 10.1038/nrrheum.2017.33

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Authors:  Lauren M F Merlo; Samantha Grabler; James B DuHadaway; Elizabeth Pigott; Kaylend Manley; George C Prendergast; Lisa D Laury-Kleintop; Laura Mandik-Nayak
Journal:  Clin Immunol       Date:  2017-02-20       Impact factor: 3.969
  1 in total
  3 in total

1.  Metabolites as drivers and targets in rheumatoid arthritis.

Authors:  Megan M Hanlon; Mary Canavan; Brianne E Barker; Ursula Fearon
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

2.  Physcion 8‑O‑β‑glucopyranoside extracted from Polygonum cuspidatum exhibits anti‑proliferative and anti‑inflammatory effects on MH7A rheumatoid arthritis‑derived fibroblast‑like synoviocytes through the TGF‑β/MAPK pathway.

Authors:  Qin Geng; Qiaofeng Wei; Shujun Wang; Huili Qi; Qin Zhu; Xia Liu; Xiaojun Shi; Shuyun Wen
Journal:  Int J Mol Med       Date:  2018-04-30       Impact factor: 4.101

Review 3.  Circulating Pro- and Anti-Inflammatory Metabolites and Its Potential Role in Rheumatoid Arthritis Pathogenesis.

Authors:  Roxana Coras; Jessica D Murillo-Saich; Monica Guma
Journal:  Cells       Date:  2020-03-30       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.